Thompson Peter A.'s Form 4 filing
Corvus Pharmaceuticals, Inc. (CRVS) · filed Sep 22, 2021
- Accession no.
- 0000947871-21-001016
- Filed
- Sep 22, 2021
- Trade date
- Sep 20, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $6.76M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Thompson Peter A.CIK 0001357522 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 20, 2021 | Common Stock, $0.0001 par value | SSaleDisposed | −1,109,644 | $6.09F1 | −$6,757,731.96 | 6,943,654 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price in column 4 is a weighted average price. These shares of the Issuer's common stock were sold in multiple transactions at prices ranging from $6.01 to $6.09. The Reporting Person undertakes to provide Corvus Pharmaceuticals, Inc., any security holder of Corvus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Referenced by the price of 1 transaction in Table I.